Regeneron Pharmaceuticals, Inc. (FRA:RGO)
Germany · Delayed Price · Currency is EUR | Market Cap | 66.58B +28.8% |
| Revenue (ttm) | 13.60B +9.3% |
| Net Income | 3.79B -2.9% |
| EPS | 35.39 +1.9% |
| Shares Out | n/a |
| PE Ratio | 17.57 |
| Forward PE | 11.04 |
| Dividend | 3.18 (0.48%) |
| Ex-Dividend Date | Aug 18, 2026 |
| Volume | 2 |
| Open | 656.90 |
| Previous Close | 662.90 |
| Day's Range | 656.90 - 656.90 |
| 52-Week Range | 476.70 - 733.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition...
Regeneron Pharmaceuticals Transcript: Collaboration
The expanded Sanofi alliance adds four long-acting antibodies, with equal sharing of development costs and global profits. The lead IL-13 program targets pivotal-study initiation in late 2027 or early 2028, while COPD data will inform a possible lunsekimig addition.
Regeneron Pharmaceuticals Slides: Collaboration
Regeneron Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Regeneron Pharmaceuticals Press release: Collaboration
Regeneron Pharmaceuticals issued a press release on October 1, 2026, disclosing material business information to investors.
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology an...
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-actin...
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed b...
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide al...
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday,...
Regeneron Pharmaceuticals Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Strong financial growth was driven by EYLEA HD, DUPIXENT, and LIBTAYO, with robust pipeline progress and upcoming key data readouts in C5, hem-onc, and Factor XI programs. Strategic focus remains on science-driven development, disciplined business development, and patient-centric initiatives.
Regeneron Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Dupixent continues to drive growth with strong performance across multiple indications and high adherence, while new pipeline assets and strategic collaborations aim to sustain leadership in immunology. Cemdisiran is poised for launch in myasthenia gravis, and EYLEA HD maintains momentum amid upcoming biosimilar competition.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FD...
Regeneron Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong financial results were driven by record sales of key products and enhanced profit recognition from collaborations. The pipeline is advancing with pivotal data and regulatory milestones expected, while commercialization and proprietary data assets position the company for future growth. Expansion of strategic alliances and new launches in neurology and obesity are key near-term priorities.
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
US FDA approves Regeneron's rare bone disorder drug
The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg
BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg, Used to Treat Various Types of Ophth...
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 ...
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. Pipeline advances and upcoming regulatory milestones support a strong outlook, while robust cash flow enables continued R&D and shareholder returns.
Regeneron Pharmaceuticals Earnings release: Q2 2026
Regeneron Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q2 2026
Regeneron Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.